Company intelligence / Profile preview

ATED Therapeutics

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

ATED Therapeutics has developed a rapid, non-invasive qPCR-based blood test that uses transfer RNA fragments as biomarkers for early Parkinson’s Disease detection, progression monitoring, and therapy response assessment; clinical validation and regulatory approval processes are ongoing.

Therapeutic areas: Neurology
Modalities: Diagnostic testSmall molecule
Industry: Molecular Diagnostics

Drug pipeline

1 asset

SuperDopa

Preclinical

Partnerships

Hebrew University of JerusalemYissum Technology Transfer Company

Beyond the preview

Go deeper on ATED Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATED Therapeutics.

Explore the full profile